Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 1, 2015, Pages 96-103

  Jeong, Byeong Ho ^a   Jeon, Kyeongman ^a   Park, Hye Yun ^a   Kim, Su Young ^a   Lee, Kyung Soo ^a   Huh, Hee Jae ^a   Ki, Chang Seok ^a   Lee, Nam Yong ^a   Shin, Sung Jae ^b   Daley, Charles L ^c   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

Ethambutol; Macrolides; Mycobacterium avium complex; Nontuberculous mycobacteria; Treatment

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; MACROLIDE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM AVIUM COMPLEX; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; CLINICAL TRIAL; COMORBIDITY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SOUTH KOREA; SPUTUM; STATISTICAL MODEL;

AGED; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; AZITHROMYCIN; CLARITHROMYCIN; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; LOGISTIC MODELS; MACROLIDES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RIFAMPIN; SPUTUM;

EID: 84920457768     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201408-1545OC     Document Type: Article

References (42)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Diseases Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. [Published erratum appears in Am J Respir Crit Care Med 2007;175:744-745.]
2. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, et al.; Nontuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013;42:1604-1613.
3. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.
4. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-982.
5. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881-886.
6. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013;19:1889-1891.
7. Russell CD, Claxton P, Doig C, Seagar AL, Rayner A, Laurenson IF. Nontuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax 2014;69:593-595.
8. Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, Ki CS, Kwon OJ. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. Tuberc Respir Dis (Seoul) 2013;75:199-204.
9. Chien JY, Lai CC, Sheng WH, Yu CJ, Hsueh PR. Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000-2012. Emerg Infect Dis 2014;20:1382-1385.
10. Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002;23:643-653.
11. Kitada S, Uenami T, Yoshimura K, Tateishi Y, Miki K, Miki M, Hashimoto H, Fujikawa T, Mori M, Matsuura K, et al. Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Int J Tuberc Lung Dis 2012;16:660-664.
12. Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, Strand MJ, Bai X, Ramamoorthy P, Rothman MS, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013;187:197-205.
13. Lee G, Lee KS, Moon JW, Koh WJ, Jeong BH, Jeong YJ, Kim HJ, Woo S. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease: natural course on serial computed tomographic scans. Ann Am Thorac Soc 2013;10:299-306.
14. Wallace RJ Jr, Cook JL, Glassroth J, Griffith DE, Olivier KN, Gordin F. American Thoracic Society statement: diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-S25.
15. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999;115: 1033-1040.
16. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004;126:566-581.
17. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005;172:250-253.
18. Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunode ficiency virus-negative patients. J Infect Dis 1998;178:121-126.
19. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-292.
20. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289.
21. Sim YS, Park HY, Jeon K, Suh GY, Kwon OJ, Koh WJ. Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Med J 2010;51:888-894.
22. Kim EY, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC, Kwon YS. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease. Korean J Intern Med 2011;26:54-59.
23. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, Shin SJ, Kwon OJ. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease. Chest 2012;142:1482-1488.
24. Lee AR, Lee J, Choi SM, Seong MW, Kim SA, Kim M, Chae KO, Lee JS, Yim JJ. Phenotypic, immunologic, and clinical characteristics of patients with nontuberculous mycobacterial lung disease in Korea. BMC Infect Dis 2013;13:558.
25. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-872.
26. Hasegawa N, Nishimura T, Ohtani S, Takeshita K, Fukunaga K, Tasaka S, Urano T, Ishii K, Miyairi M, Ishizaka A. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009;136:1569-1575.
27. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012;18:436-443.
28. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;185:575-583.
29. Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, Yamada T, Masuda M, Inui N, Chida K, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease: a preliminary study. Ann Am Thorac Soc 2014;11: 23-29.
30. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-348.
31. Lee G, Kim HS, Lee KS, Koh WJ, Jeon K, Jeong BH, Ahn J. Serial CT findings of nodular bronchiectatic Mycobacterium avium complex pulmonary disease with antibiotic treatment. AJR Am J Roentgenol 2013;201:764-772.
32. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI Document No. M24-A2.
33. Xu HB, Jiang RH, Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2014;33:347-358.
34. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153: 1766-1772.
35. Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014;146:276-282.
36. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001;32:1547-1553.
37. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 2006;12:195-202.
38. Fujikane T, Fujiuchi S, Yamazaki Y, Sato M, Yamamoto Y, Takeda A, Nishigaki Y, Fujita Y, Shimizu T. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 2005;9:1281-1287.
39. Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y, Yasuda K, Suda T, Nakamura H, Chida K. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings. Eur Respir J 2008;32:147-152.
40. Grif fith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012;25:218-227.
41. Wallace RJ Jr, Zhang Y, Brown BA, Dawson D, Murphy DT, Wilson R, Griffith DE. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998;158:1235-1244.
42. Wallace RJ Jr, Zhang Y, Brown-Elliott BA, Yakrus MA, Wilson RW, Mann L, Couch L, Girard WM, Griffith DE. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002;186:266-273.